** Shares of drug developer Q32 Bio fall 67.64% to $7.90 after market
** QTTB says its experimental drug bempikibart failed to meet the main goal in a part of a mid-stage trial studying it in patients with atopic dermatitis
** The two-part trial was evaluating the drug in adults with atopic dermatitis, a condition that causes dry, itchy and inflamed skin
** Co plans to conduct a review to better understand the results
** In another trial, bempikibart showed improvement in patients with alopecia areata, an autoimmune disease that causes hair loss in patches
** Based on the results, QTTB plans to advance development of bempikibart in patients with the hair condition
** Up to last close, stock up ~123% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。